All In Biotech

Drug Trial Radar · NCT07898774

A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients

A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jan 21, 2027

Primary completion

Jan 17, 2031

Study completion Jan 17, 2031

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients

Conditions

  • C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
  • Recurrent Glomerular Disease After Kidney Transplantation

Interventions

  • PegcetacoplanDrug

    Dose amount based on age and weight Subcutaneous infusion twice-a-week. Adult participants aged 18 years or older at enrolment: 1080 mg Adolescent participants aged 12 to 17 years at enrolment: * Weight ≥50 kg: 1080 mg * Weight 35 to \<50 kg: 648 mg 1st dose, then 810 mg subsequently * Weight 30 to \<35 kg: 540 mg for the first 2 doses, then 648 mg subsequently

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Clinically Significant Recurrent DiseaseTime frame: Within 2 years after kidney transplantation

Locations

33 sites in 10 countries. Site status is shown where the registry gives one.

  • Real Hospital Português

    Recife, Pernambuco, Brazil · Not yet recruiting

  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu

    Botucatu, São Paulo, Brazil · Not yet recruiting

  • Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP

    São Paulo, São Paulo, Brazil · Not yet recruiting

  • University of Alberta - Faculty of Medicine & Dentistry

    Edmonton, Alberta, Canada · Not yet recruiting

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada · Not yet recruiting

  • London Health Sciences Centre (LHSC) - University Hospital

    London, Ontario, Canada · Not yet recruiting

  • Toronto General Hospital

    Toronto, Ontario, Canada · Not yet recruiting

  • McGill University Health Centre Research Institute

    Montreal, Quebec, Canada · Not yet recruiting

  • Helsinki University Central Hospital

    Helsinki, Finland · Not yet recruiting

  • CHU Strasbourg - Nouvel Hôpital Civil

    Strasbourg, Bas Rhin, France · Not yet recruiting

  • Hopital Rangueil

    Toulouse, Haute Garonne, France · Not yet recruiting

  • Hopital Lapeyronie pt

    Montpellier, Herault, France · Not yet recruiting

  • Hopital Claude Huriez - CHU Lille

    Lille, Nord, France · Not yet recruiting

  • Hôpital Necker - Enfants Malades

    Paris, Paris, France · Not yet recruiting

  • Hopital Edouard Herriot - CHU Lyon

    Lyon, Rhone, France · Not yet recruiting

  • Medizinische Hochschule Hannover

    Hanover, Lower Saxony, Germany · Not yet recruiting

  • Universitaetsklinikum Koeln

    Cologne, North Rhine-Westphalia, Germany · Not yet recruiting

  • Universitaetsklinikum Essen

    Essen, North Rhine-Westphalia, Germany · Not yet recruiting

  • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari

    Bari, Bari, Italy · Not yet recruiting

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)

    Bergamo, Bergamo, Italy · Not yet recruiting

  • Ospedale Pediatrico Bambino Gesù

    Roma, Roma, Italy · Not yet recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Roma, Italy · Not yet recruiting

  • King Faisal Specialist Hospital & Research Center

    Riyadh, Saudi Arabia · Not yet recruiting

  • Hospital Universitari Vall d'Hebron - VHIR

    Barcelona, Barcelona, Spain · Not yet recruiting

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, La Coruña, Spain · Not yet recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain · Not yet recruiting

  • Hospital Regional Universitario de Malaga

    Málaga, Málaga, Spain · Not yet recruiting

  • Hospital de Cruces

    Barakaldo, Vizcaya, Spain · Not yet recruiting

  • Centre Hospitalier Universitaire Vaudois (CHUV)

    Lausanne, Switzerland · Not yet recruiting

  • Royal Free Hospital

    London, Greater London, United Kingdom · Not yet recruiting

  • Hammersmith Hospital

    London, Greater London, United Kingdom · Recruiting

  • Manchester Royal Infirmary

    Manchester, Greater Manchester, United Kingdom · Not yet recruiting

  • Freeman Hospital

    Newcastle upon Tyne, Tyne & Wear, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.